Trial Profile
A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Registrational
- Acronyms INN-MS
- 04 Sep 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2024.
- 04 Sep 2023 Planned primary completion date changed from 1 May 2022 to 1 May 2024.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.